Hostname: page-component-669899f699-g7b4s Total loading time: 0 Render date: 2025-04-30T16:54:46.287Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of ivabradine in tachycardia due to hyperthyroidism in a child: a case report and literature review

Published online by Cambridge University Press:  24 February 2025

Mehtap Küçük Open the ORCID record for Mehtap Küçük [Opens in a new window] ,
İlkay Erdoğan Open the ORCID record for İlkay Erdoğan [Opens in a new window] ,
Birgül Varan  and
N. Kürşad Tokel
Mehtap Küçük*
Affiliation:
Division of Cardiology, Department of Pediatrics, Başkent University Ankara Hospital, Ankara, Turkey
İlkay Erdoğan
Affiliation:
Division of Cardiology, Department of Pediatrics, Başkent University Ankara Hospital, Ankara, Turkey
Birgül Varan
Affiliation:
Division of Cardiology, Department of Pediatrics, Başkent University Ankara Hospital, Ankara, Turkey
N. Kürşad Tokel
Affiliation:
Division of Cardiology, Department of Pediatrics, Başkent University Ankara Hospital, Ankara, Turkey
*
Corresponding author: Mehtap Küçük; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Sinus tachycardia due to hyperthyroidism is generally treated with beta-blockers. But some patients do not respond to beta-blockers or may have non-tolerable side effects or have contraindications. We presented a case with persistent sinus tachycardia secondary to hyperthyroidism refractory to maximal doses of propranolol. After ivabradine treatment, her heart rate was < 100 bpm within 24 hours. There were no electrocardiogram changes or side effects. The use of ivabradine is promising and can be considered in cases where tachycardia cannot be controlled in children with hyperthyroidism.

Keywords

ChildGraves’ diseasehyperthyroidismivabradinetachycardiathyrotoxicosis
Type
Original Article
Information
Cardiology in the Young , Volume 35 , Issue 3 , March 2025 , pp. 600 - 603
Check for updates
Copyright
© The Author(s), 2025. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Mooij, CF, Cheetham, TD, Verburg, FA, et al. 2022 European thyroid association guideline for the management of pediatric graves’ disease. Eur Thyroid J 2022; 11: 1–17. DOI: 10.1530/ETJ-21-0073.Google ScholarPubMed
Biondi, B. Mechanisms in endocrinology: heart failure and thyroid dysfunction. Eur J Endocrinol 2012; 167: 609–618. DOI: 10.1530/EJE-12-0627.Google Scholar
Go, MT, George, AM, Tahsin, B, et al. Tachycardia in hyperthyroidism: not so common. Plos One 2022; 17: 1–10. DOI: 10.1371/journal.pone.0273724.Google Scholar
Osman, F, Gammage, MD, Sheppard, MC, et al. Cardiac dysrhythmias and thyroid dysfunction-the hidden menace? J Clin Endocrinol Metab 2002; 87: 963–967. DOI: 10.1210/jcem.87.3.8217.CrossRefGoogle ScholarPubMed
Kim, BH, Cho, KI, Kim, SM, et al. Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat. Heart Vessels 2013; 28: 524–535. DOI: 10.1007/s00380-012-0304-z.CrossRefGoogle ScholarPubMed
Medina, Y, Khan, A, Spagnola, J, et al. Resolution of sinus tachycardia secondary to hyperthyroidism with ivabradine. J J Clin Med Res 2023; 15: 336–339. DOI: 10.14740/jocmr4940.Google ScholarPubMed
Romeo, E, Grimaldi, N, Sarubbi, B, et al. A pediatric case of cardiomyopathy induced by inappropriate sinus tachycardia: efficacy of ivabradine. Pediatr Cardiol 2011; 32: 842–845. DOI: 10.1007/s00246-011-9964-1.Google ScholarPubMed
Ptaszynski, P, Kaczmarek, K, Ruta, J, et al. Ivabradine in combination with metoprolol succinate in the treatment of inappropriate sinus tachycardia. J Cardiovasc Pharmacol Ther 2013; 18: 338–344. DOI: 10.1177/1074248413478172.CrossRefGoogle ScholarPubMed
Tagami, T, Yambe, Y, Tanaka, T, et al. Short-term effects of β-adrenergic antagonists and Methimazole in new-onset thyrotoxicosis caused by graves” disease. Intern Med 2012; 51: 2285–2290. DOI: 10.2169/internalmedicine.51.7302.CrossRefGoogle ScholarPubMed
Alam, ST, Zaman, J. Case study of thyrotoxic cardiomyopathy. BMJ Case Rep 2019; 12: 1–4. DOI: 10.1136/bcr-2018-228896.Google ScholarPubMed
Donne, GD, Roses-Noguer, F, Till, J, et al. Ivabradine in the paediatric population: preliminary findings. J Am Coll Cardiol 2016; 67: 774–774. DOI: 10.1016/S0735-1097(16)30775-6.CrossRefGoogle Scholar
Nawarskas, JJ, Bowman, BN, Anderson, JR. Ivabradine: a unique and intriguing medication for treating cardiovascular disease. Cardiol Rev 2015; 23: 201–211. DOI: 10.1097/CRD.0000000000000070.CrossRefGoogle ScholarPubMed